Optimal duration of dual antiplatelet therapy for coronary artery disease
SourceNetherlands Heart Journal, 26, 6, (2018), pp. 321-333
Article / Letter to editor
Display more detailsDisplay less details
Netherlands Heart Journal
SubjectRadboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences
The optimal duration of dual antiplatelet therapy (DAPT) for stable coronary artery disease and acute coronary syndrome is a complex decision. We review current literature on standard duration DAPT versus short duration DAPT (6 months or shorter) or extended duration DAPT (>12 months) after percutaneous coronary intervention with drug-eluting stent placement, and prolonged treatment after 12 months in acute coronary syndrome. Current guideline recommendations are summarised, including the use of risk scores for ischaemic and bleeding risk assessment. Because of the limitations of current risk scores, we propose multiple patient-related and procedure-related factors for the ischaemic and bleeding risk assessment aiding in personalised DAPT duration.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.